Corcept Beginning Mifepristone Pivotal Trials For Psychotic Depression
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Corcept will begin the first of two pivotal Phase III trials for Corlux (mifepristone) for treatment of psychotic features of psychotic major depression "immediately," the firm said.